Switch from Symbicort Turbuhaler to Bufomix Easyhaler; a real-life prospective study in asthma patients
P. Rytilä (Espoo, Finland), J. Syk (Stockholm, Sweden), I. Vinge (Lidingö, Sweden), M. Sörberg (Sollentuna, Sweden)
Source: International Congress 2018 – Clinical markers of asthma
Session: Clinical markers of asthma
Session type: Thematic Poster
Number: 3998
Disease area: Airway diseases
Abstract INTRODUCTION: It has been suggested that change of inhaler may influence asthma control. However, meta-analyses indicate that all inhalers can achieve the same therapeutic effect if patients can apply the correct inhalation technique.
OBJECTIVE: The main aim of the study was to demonstrate non-inferiority of asthma control when switching inhaler from Symbicort Turbuhaler to Bufomix Easyhaler.
METHODS: This was an open, prospective, non-interventional, multicentre, single arm study. Adult asthmatics using Symbicort Turbuhaler regularly for at least six months were consecutively recruited from seven Swedish primary health care centres and switched to Bufomix Easyhaler with the same dose. Asthma Control Test (ACT), Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) and spirometry were performed before switching inhalers and after 12 weeks. Check of inhaler technique was performed before switching and two weeks after switching according to the centres routine.
RESULTS: Altogether 125 patients were included and 117 completed the study. Five patients were lost to follow up and 3 due to adverse events. ACT mean score improved from 19.04 to 20.76 (p=0.001, 95%CI 0.81-2.63) and Mini-AQLQ mean score improved from 5.44 to 5.78 (p=0.001, 95%CI 0.18-0.49), neither of them considered as a clinically important improvement. Spirometry, FEV1 and FVC percent of predicted showed no statistically or clinically significant changes.
CONCLUSION: Patients switching from Symbicort Turbuhaler to Bufomix Easyhaler had equivalent or better results regarding patient´s control of their asthma.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Rytilä (Espoo, Finland), J. Syk (Stockholm, Sweden), I. Vinge (Lidingö, Sweden), M. Sörberg (Sollentuna, Sweden). Switch from Symbicort Turbuhaler to Bufomix Easyhaler; a real-life prospective study in asthma patients. 3998
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Switch to Budesonide/Formoterol Easyhaler Inhalation from other inhalers in asthma patients; A real-life study Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Addition of formoterol Turbuhaler® to budesonide Turbuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial Source: Eur Respir J 2001; 18: Suppl. 33, 330s Year: 2001
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Safety of formoterol turbuhaler when used as a reliever therapy in asthma (the RELIEF study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Patient inhaler satisfaction with Spiromax Budesonide/Formoterol versus Diskus Fluticasone/Salmeterol in COPD Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007